Affiliation:
1. Unit of Infectious Diseases, Microbiology, and Preventive Medicine and Biomedical Institute of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Sevilla, Seville, Spain
Abstract
ABSTRACT
LpxC inhibitors have generally shown poor
in vitro
activity against
Acinetobacter baumannii
. We show that the LpxC inhibitor PF-5081090 inhibits lipid A biosynthesis, as determined by silver staining and measurements of endotoxin levels, and significantly increases cell permeability. The presence of PF-5081090 at 32 mg/liter increased susceptibility to rifampin, vancomycin, azithromycin, imipenem, and amikacin but had no effect on susceptibility to ciprofloxacin and tigecycline. Potentiating existing antibiotics with LpxC inhibitors may represent an alternative treatment strategy for multidrug-resistant
A. baumannii
.
Funder
ISCIII European Development Regional Fund, A Way to Achieve Europe
Spanish Network for Research in Infectious Diseases
Consejeria de Empresa, Empleo y Comercio de la Junta de Andalucia
Subprograma Miguel Servet, Ministerio de Economia y Competitividad
Subprograma Sara Borrel, Ministerio de Economia y Competitividad
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献